Bio-Techne Corp (TECH)

$68.67 -1.29 (-1.84%)
Market Cap 10.66B
Revenue (ttm) 1.22B
Net Income (ttm) 73.40M
EPS (ttm) N/A
PE Ratio 38.58
Forward PE 39.78
Profit Margin 6.02%
Debt to Equity Ratio 0.15
Volume 3,533,800
Avg Vol 1,931,980
Day's Range N/A - N/A
Shares Out 155.81M
Stochastic %K 94%
Beta 1.47
Analysts Strong Sell
Price Target $68.58

Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth f...

Industry: Biotechnology
Sector: Healthcare
Phone: 612 379 8854
Fax: 612 656 4400
Address:
614 McKinley Place N.E., Minneapolis, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 16 at 11:29 AM
$TECH RSI: 90.10, MACD: 2.1306 Vol: 4.06, MA20: 62.04, MA50: 61.17 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 14 at 6:02 PM
$TECH Current Stock Price: $67.11 Contracts to trade: $65 TECH Jan 16 2026 Call Entry: $1.85 Exit: $2.60 ROI: 41% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Fizz26
Fizz26 Jan. 13 at 2:38 PM
$DJIA $TECH !!!
0 · Reply
DoughCook
DoughCook Jan. 13 at 1:44 AM
$TECH — The selloff rounded out instead of breaking. Rounding bottom completes as price lifts into a fresh breakout.
0 · Reply
50bps
50bps Jan. 6 at 2:54 AM
$TECH ty for the downgrade
0 · Reply
SPYmyQQQ
SPYmyQQQ Jan. 5 at 6:44 PM
🎯 Target Hit 🏁 📨 From Dec 11, 2025 🏛️ $TECH 💵 Entry: $59.9200 ✅ Exit: $61.6757 💰 P/L: +2.93% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 29 at 5:52 PM
$TECH Current Stock Price: $59.03 Contracts to trade: $60 TECH Jan 16 2026 Call Entry: $1.70 Exit: $2.79 ROI: 64% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
TrendValueNavigator
TrendValueNavigator Dec. 27 at 8:26 AM
$TECH Expectations are resetting toward sustainable results, not one‑off wins. Cash discipline will likely dictate investor patience. Missteps now carry a higher penalty than in prior cycles. Patience is warranted — but must be supported by results.
0 · Reply
NuNavigator
NuNavigator Dec. 26 at 6:40 AM
$TECH This name increasingly trades on execution rhythm rather than speculation about possibilities. Governance alignment matters more at this stage. Operational wins could gradually shift expectations upward. Execution precision is the primary catalyst from here.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 9:12 AM
$TECH RSI: 33.58, MACD: -0.6960 Vol: 2.57, MA20: 60.47, MA50: 60.93 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on TECH
Bio-Techne Corporation (TECH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 2:46 PM EST - 3 days ago

Bio-Techne Corporation (TECH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference

Dec 23, 2025, 7:00 AM EST - 24 days ago

Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference

Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis

Dec 9, 2025, 6:30 AM EST - 5 weeks ago

Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis

Bio-Techne Corporation (TECH) Presents at 53rd Annual Nasdaq Investor Conference Transcript

Dec 9, 2025, 5:57 AM EST - 5 weeks ago

Bio-Techne Corporation (TECH) Presents at 53rd Annual Nasdaq Investor Conference Transcript

Bio-Techne Corporation (TECH) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 6:43 PM EST - 6 weeks ago

Bio-Techne Corporation (TECH) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 2:33 PM EST - 6 weeks ago

Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript

Bio-Techne to Present at Upcoming Investor Conferences

Nov 25, 2025, 7:00 AM EST - 7 weeks ago

Bio-Techne to Present at Upcoming Investor Conferences

Bio-Techne Corporation (TECH) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 9:43 AM EST - 2 months ago

Bio-Techne Corporation (TECH) Presents at Jefferies London Healthcare Conference 2025 Transcript

Bio-Techne Corporation (TECH) Presents at Stephens Annual Investment Conference 2025 Transcript

Nov 18, 2025, 4:38 PM EST - 2 months ago

Bio-Techne Corporation (TECH) Presents at Stephens Annual Investment Conference 2025 Transcript

Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio

Nov 18, 2025, 6:30 AM EST - 2 months ago

Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio

Bio-Techne Corporation (TECH) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 11, 2025, 11:41 AM EST - 2 months ago

Bio-Techne Corporation (TECH) Presents at Stifel 2025 Healthcare Conference Transcript

Bio-Techne Corporation (TECH) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 1:01 PM EST - 2 months ago

Bio-Techne Corporation (TECH) Presents at UBS Global Healthcare Conference 2025 Transcript

Bio-Techne Corporation (TECH) Q1 2026 Earnings Call Transcript

Nov 5, 2025, 1:11 PM EST - 2 months ago

Bio-Techne Corporation (TECH) Q1 2026 Earnings Call Transcript

Bio-Techne misses quarterly sales estimates on weak biotech demand

Nov 5, 2025, 7:22 AM EST - 2 months ago

Bio-Techne misses quarterly sales estimates on weak biotech demand

Bio-Techne Releases First Quarter Fiscal 2026 Results

Nov 5, 2025, 6:30 AM EST - 2 months ago

Bio-Techne Releases First Quarter Fiscal 2026 Results

BIO-TECHNE DECLARES DIVIDEND

Nov 5, 2025, 6:30 AM EST - 2 months ago

BIO-TECHNE DECLARES DIVIDEND

AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients

Nov 4, 2025, 9:01 AM EST - 2 months ago

AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients

ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics

Nov 3, 2025, 7:00 AM EST - 2 months ago

ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics

Bio-Techne Launches ProximityScope™ Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research

Oct 28, 2025, 6:30 AM EDT - 2 months ago

Bio-Techne Launches ProximityScope™ Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research

ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at Children's National Hospital

Oct 23, 2025, 7:00 AM EDT - 3 months ago

ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at Children's National Hospital

Saguaro Biosciences Partners with Bio-Techne to Distribute Innovative Live-Cell Imaging Reagents

Oct 15, 2025, 9:00 AM EDT - 3 months ago

Saguaro Biosciences Partners with Bio-Techne to Distribute Innovative Live-Cell Imaging Reagents

Bio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter Fiscal 2026 Financial Results

Oct 15, 2025, 7:00 AM EDT - 3 months ago

Bio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter Fiscal 2026 Financial Results

Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032

Oct 9, 2025, 7:00 AM EDT - 3 months ago

Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032

Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications

Sep 26, 2025, 6:30 AM EDT - 4 months ago

Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications

Bio-Techne Highlights Progress on Climate, Innovation, and Culture in 2025 Sustainability Report

Sep 24, 2025, 6:59 AM EDT - 4 months ago

Bio-Techne Highlights Progress on Climate, Innovation, and Culture in 2025 Sustainability Report

Bio-Techne Corporation (TECH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 2:36 PM EDT - 4 months ago

Bio-Techne Corporation (TECH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Bio-Techne Corporation (TECH) Presents At Baird Global Healthcare Conference 2025 Transcript

Sep 9, 2025, 11:36 AM EDT - 4 months ago

Bio-Techne Corporation (TECH) Presents At Baird Global Healthcare Conference 2025 Transcript

ScaleReady Awards G-Rex® Grants to Support Cell and Gene Therapy Manufacturing in California

Sep 9, 2025, 7:00 AM EDT - 4 months ago

ScaleReady Awards G-Rex® Grants to Support Cell and Gene Therapy Manufacturing in California

Bio-Techne Corporation (TECH) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 3, 2025, 3:42 PM EDT - 4 months ago

Bio-Techne Corporation (TECH) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

ScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory

Aug 14, 2025, 7:00 AM EDT - 5 months ago

ScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory

Bio-Techne Corporation (TECH) Q4 2025 Earnings Call Transcript

Aug 6, 2025, 12:52 PM EDT - 5 months ago

Bio-Techne Corporation (TECH) Q4 2025 Earnings Call Transcript

Bio-Techne beats quarterly estimates on strength in protein sciences unit

Aug 6, 2025, 8:08 AM EDT - 5 months ago

Bio-Techne beats quarterly estimates on strength in protein sciences unit

Bio-Techne Releases Fourth Quarter Fiscal 2025 Results

Aug 6, 2025, 6:30 AM EDT - 5 months ago

Bio-Techne Releases Fourth Quarter Fiscal 2025 Results

Bio-Techne Announces Exosome Diagnostics Divestiture

Aug 5, 2025, 4:30 PM EDT - 5 months ago

Bio-Techne Announces Exosome Diagnostics Divestiture

ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine

Aug 5, 2025, 7:00 AM EDT - 5 months ago

ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

Jul 31, 2025, 9:52 AM EDT - 6 months ago

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

BSX CAH DXCM EW ISRG LLY PODD

ScaleReady announces multiple G-Rex® Grants have been awarded to investigators at University of Minnesota's Center for Genome Engineering

Jul 31, 2025, 7:00 AM EDT - 6 months ago

ScaleReady announces multiple G-Rex® Grants have been awarded to investigators at University of Minnesota's Center for Genome Engineering

Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell

Jul 28, 2025, 1:19 PM EDT - 6 months ago

Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell

Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results

Jul 17, 2025, 7:00 AM EDT - 6 months ago

Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results

Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology

Jul 15, 2025, 9:03 AM EDT - 6 months ago

Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology

Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection

Jul 15, 2025, 7:00 AM EDT - 6 months ago

Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

Jul 14, 2025, 7:00 AM EDT - 6 months ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

ABEO

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

Jun 24, 2025, 7:00 AM EDT - 7 months ago

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

Jun 10, 2025, 7:00 AM EDT - 7 months ago

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

Bio-Techne to Present at Investor Conferences

May 29, 2025, 7:00 AM EDT - 8 months ago

Bio-Techne to Present at Investor Conferences

ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA)

May 14, 2025, 7:00 AM EDT - 8 months ago

ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA)

Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025

May 12, 2025, 7:00 AM EDT - 8 months ago

Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025

Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing

May 8, 2025, 9:30 AM EDT - 9 months ago

Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing

Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

May 8, 2025, 7:00 AM EDT - 9 months ago

Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript

May 7, 2025, 10:38 AM EDT - 9 months ago

Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript

OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 16 at 11:29 AM
$TECH RSI: 90.10, MACD: 2.1306 Vol: 4.06, MA20: 62.04, MA50: 61.17 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 14 at 6:02 PM
$TECH Current Stock Price: $67.11 Contracts to trade: $65 TECH Jan 16 2026 Call Entry: $1.85 Exit: $2.60 ROI: 41% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Fizz26
Fizz26 Jan. 13 at 2:38 PM
$DJIA $TECH !!!
0 · Reply
DoughCook
DoughCook Jan. 13 at 1:44 AM
$TECH — The selloff rounded out instead of breaking. Rounding bottom completes as price lifts into a fresh breakout.
0 · Reply
50bps
50bps Jan. 6 at 2:54 AM
$TECH ty for the downgrade
0 · Reply
SPYmyQQQ
SPYmyQQQ Jan. 5 at 6:44 PM
🎯 Target Hit 🏁 📨 From Dec 11, 2025 🏛️ $TECH 💵 Entry: $59.9200 ✅ Exit: $61.6757 💰 P/L: +2.93% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 29 at 5:52 PM
$TECH Current Stock Price: $59.03 Contracts to trade: $60 TECH Jan 16 2026 Call Entry: $1.70 Exit: $2.79 ROI: 64% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
TrendValueNavigator
TrendValueNavigator Dec. 27 at 8:26 AM
$TECH Expectations are resetting toward sustainable results, not one‑off wins. Cash discipline will likely dictate investor patience. Missteps now carry a higher penalty than in prior cycles. Patience is warranted — but must be supported by results.
0 · Reply
NuNavigator
NuNavigator Dec. 26 at 6:40 AM
$TECH This name increasingly trades on execution rhythm rather than speculation about possibilities. Governance alignment matters more at this stage. Operational wins could gradually shift expectations upward. Execution precision is the primary catalyst from here.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 9:12 AM
$TECH RSI: 33.58, MACD: -0.6960 Vol: 2.57, MA20: 60.47, MA50: 60.93 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JackDarwin
JackDarwin Dec. 11 at 1:26 PM
$TECH Bullish Tweezer Candlestick Pattern Formed
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Dec. 11 at 11:41 AM
$TECH Bio-Techne's Lunaphore Collaborates With Wyss Center For Bio And Neuroengineering To Develop Automated Workflow For Simultaneous RNA And Protein Detection In 3D Specimens
0 · Reply
OptionRunners
OptionRunners Dec. 5 at 8:25 PM
$TECH buyer of the January 16th 2026 $60/$55/$75 bear seagulls 5,000 times for $1.22
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 4 at 1:22 PM
$TECH Current Stock Price: $63.85 Contracts to trade: $65 TECH Dec 19 2025 Call Entry: $1.47 Exit: $2.85 ROI: 94% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 10:51 AM
$TE $TEAM $TECH $TECL $TECX
0 · Reply
smartkarma
smartkarma Nov. 28 at 6:07 AM
$TECH | Bio-Techne Braces for a Biotech Funding Revival—Is a Major Upswing Ahead? "Bio-Techne delivered its first-quarter fiscal year 2026 results amidst a challenging market environment. Despite the company’s strategic and..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/bio-techne-braces-for-a-biotech-funding-revival-is-a-major-upswing-ahead
0 · Reply
smartkarma
smartkarma Nov. 28 at 6:02 AM
$TECH | Bio-Techne Braces for a Biotech Funding Revival—Is a Major Upswing Ahead? "Bio-Techne delivered its first-quarter fiscal year 2026 results amidst a challenging market environment. Despite the company’s strategic and..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/bio-techne-braces-for-a-biotech-funding-revival-is-a-major-upswing-ahead
0 · Reply
SPYmyQQQ
SPYmyQQQ Nov. 24 at 7:53 PM
🎯 Target Hit 🏁 📨 From Nov 12, 2025 🏛️ $TECH 💵 Entry: $61.3900 ✅ Exit: $63.1028 💰 P/L: +2.79% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 5:50 PM
$TE $TEAM 🔥 $TECH $TECL $TECX 🔥
0 · Reply
JarvisFlow
JarvisFlow Nov. 20 at 2:13 PM
Argus Research has updated their rating for Bio-Techne ( $TECH ) to Buy with a price target of 68.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Nov. 14 at 4:03 PM
$TECH RSI: 32.64, MACD: 0.0440 Vol: 2.51, MA20: 61.66, MA50: 58.10 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Jimmy3Stylz
Jimmy3Stylz Nov. 11 at 2:26 PM
$TECH congress doesn’t miss! https://x.com/pelositracker/status/1987934381005304006?s=61&t=3Qx9I7Gngmu8kjm-5F7m9Q
1 · Reply